The Acutis SARS-CoV-2 test is a multiplex assay that targets three key genes-ORF1ab, N, and E, that scientists believe are key to accurately identifying the presence of the virus in patient samples. 8186 LARK BROWN RD STE 103 Elkridge, MD 21075. Elkton, MD: Wilmington, DE: Las Vegas, NV: North East, MD.
We leverage science, technology and innovation to accomplish our mission getting you answers that help you make clear, confident decisions about your health. Senior Vice President and Chief Financial Officer in Acutis Diagnostics. We are thankful to our development partners who have worked diligently along with our scientists, not only in providing some of the key validation material but also in ensuring us that they will be able to keep up with the demand that we have been seeing nationwide." We are a global life sciences and healthcare company, and our mission is simple: improve health, improve lives. This process, whereby we performed prescribed validation steps using various sample types, provided us with a deeper understanding of the assay than we might have experienced otherwise. "While offering an assay based on an EUA obtained by a diagnostic manufacturer rather pursuing our own might have been simpler, our team felt that by using our skill set honed in the design of our other molecular assays, it would allow us to provide the most effective solution to our clients. "We are very proud of our outstanding research and development team who have worked tirelessly on this validation," commented Jibreel Sarij, CEO. As a superior diagnostics lab, we take our responsibility to the medical community seriously, by delivering answers fast when patients need them the most. Compliance Manager at Acutis Diagnostics Shirley, NY. The assay will use a standard nasopharyngeal specimen from which Acutis will extract viral RNA and then test for the presence of key genes that can be used to identify its presence. At Acutis, our comes from the providers we service. Headquarters Regions Greater New York Area, East Coast, Northeastern US. Jiabin Tang PhD Senior Director of Precision Oncology New York, NY. The assay will be available beginning Monday, Maand will be run under an Emergency Use Authorization granted to Acutis from the FDA. EAST NORTHPORT, N.Y., Ma/PRNewswire-PRWeb/ - Acutis Diagnostics, a clinical diagnostics laboratory headquartered in New York, announced today that it has released a multiplex laboratory test for the detection of SARS-CoV-2, the causative agent of COVID-19.
0 kommentar(er)
